(C) 2011 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:461-470″
“Dysoxylum mollissimum Blume, the accepted name of the species known by more than a dozen names has been extensively studied for its chemical constituents under the name Dysoxylum hainanense Merr. Congruent with the observation that the chemical constituents of this species might be affected by its geographic distribution, the leaf samples of this species from Quezon Province, Philippines
Entinostat inhibitor were investigated. The dichloromethane extract of the air-dried leaves of D. mollissimum Blume afforded four new glabretal-type triterpenoids (1a-2b) along with the known compounds, 24,25-epoxy-3 beta,23-dihydroxy-7-tirucallene (3), squalene, polyprenol, linoleic acid and lutein. The structures of 1a-2b were elucidated by extensive 1D and 2D NMR spectroscopy and confirmed by mass spectrometry. (C) 2013 Phytochemical Society of Europe. Published Emricasan by Elsevier B.V. All rights reserved.”
“P>A 24-year-old man was admitted for a painful gingival ulcer. Histology and immunohistochemistry
of a lesional biopsy revealed the diagnosis of Langerhans cell histiocytosis (LCH). To rule out multifocal disease, a complete staging was performed. There was no evidence of bony lesions or any other organ involvement. The diagnosis of LCH restricted to the oral mucosa was established. The complete oral lesion was ablated by CO(2) laser and subsequently treated topically with triamcinolone acetonide. The patient is still in remission after one year of follow-up.
LCH confined to the oral mucosa is rare. It presents usually as an inflammatory or ulcerative lesion, easily leading to misinterpretation and delayed diagnosis. Patients with limited unifocal check details mucocutaneous disease, as in the present
case, usually have an excellent prognosis. However, the oral lesion may represent an early sign of LCH, predating and progressing to an aggressive life-threatening multiorgan disease.”
“Objective: To evaluate the independent impact of congestive heart failure (CHF) status (compensation or decompensation) on serum uric acid levels among men with high cardiovascular risk profile.
Method: We analyzed 11,681 men from the Multiple Risk Factor Interventional Trial, using data prospectively collected at baseline and annually over 6 years (64,644 visits). We evaluated the impact of change in CHF status during study follow-up, as compared with study baseline, on hyperuricemia (serum uric acid >= 7 mg/dL) and serum uric acid levels, using generalized estimating equations, adjusting for age, race, weight, weight change, education, alcohol intake, diuretic use, hypertension, serum creatinine level, and dietary factors. Similarly, we evaluated the independent impact of change in diuretic use (initiation or discontinuation).
Results: At baseline, mean serum uric acid was 6.88 mg/dL. Compared with no change in CHF status, odds ratios of hyperuricemia were 1.